Literature DB >> 18181180

Identification of a novel and myeloid specific role of the leukemia-associated fusion protein DEK-NUP214 leading to increased protein synthesis.

Malin Ageberg1, Kristina Drott, Tor Olofsson, Urban Gullberg, Anders Lindmark.   

Abstract

The t(6;9)(p22;q34) chromosomal translocation is found in a subset of patients with acute myeloid leukemia (AML). The translocation results in a fusion between the nuclear phosphoprotein DEK and the nucleoporin NUP214 (previously CAN). The mechanism by which the fusion protein DEK-NUP214 contributes to leukemia development has not been identified, and disruptions of normal cellular functions by DEK-NUP214 have previously not been described. In the present study, a novel effect of the DEK-NUP214 fusion protein is demonstrated. Our findings reveal a substantial increase in global protein synthesis in DEK-NUP214 expressing cells. Furthermore, we conclude that this effect is not the result of dysregulated transcription but merely due to increased translation. Consistent with the association with AML, the increased protein synthesis mediated by DEK-NUP214 is restricted to cells of the myeloid lineage. Analysis of potential mechanisms for regulating protein synthesis shows that expression of DEK-NUP214 correlates to the phosphorylation of the translation initiation protein, EIF4E. The present data provide evidence that increase of translational activity constitutes a mechanism by which the leukemogenic effect of DEK-NUP124 may be mediated. (c) 2008 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18181180     DOI: 10.1002/gcc.20531

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  14 in total

1.  The C. elegans homolog of nucleoporin Nup98 is required for the integrity and function of germline P granules.

Authors:  Ekaterina Voronina; Geraldine Seydoux
Journal:  Development       Date:  2010-03-24       Impact factor: 6.868

Review 2.  Control of tumorigenesis and chemoresistance by the DEK oncogene.

Authors:  Erica Riveiro-Falkenbach; María S Soengas
Journal:  Clin Cancer Res       Date:  2010-05-25       Impact factor: 12.531

Review 3.  The DEK oncoprotein and its emerging roles in gene regulation.

Authors:  C Sandén; U Gullberg
Journal:  Leukemia       Date:  2015-03-13       Impact factor: 11.528

Review 4.  Nucleoporin genes in human diseases.

Authors:  Valeria Nofrini; Danika Di Giacomo; Cristina Mecucci
Journal:  Eur J Hum Genet       Date:  2016-04-13       Impact factor: 4.246

5.  t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients.

Authors:  Julie Damgaard Sandahl; Eva A Coenen; Erik Forestier; Jochen Harbott; Bertil Johansson; Gitte Kerndrup; Souichi Adachi; Anne Auvrignon; H Berna Beverloo; Jean-Michel Cayuela; Lucy Chilton; Maarten Fornerod; Valérie de Haas; Christine J Harrison; Hiroto Inaba; Gertjan J L Kaspers; Der-Cherng Liang; Franco Locatelli; Riccardo Masetti; Christine Perot; Susana C Raimondi; Katarina Reinhardt; Daisuke Tomizawa; Nils von Neuhoff; Marco Zecca; C Michel Zwaan; Marry M van den Heuvel-Eibrink; Henrik Hasle
Journal:  Haematologica       Date:  2014-01-17       Impact factor: 9.941

Review 6.  Nuclear pore proteins and cancer.

Authors:  Songli Xu; Maureen A Powers
Journal:  Semin Cell Dev Biol       Date:  2009-03-18       Impact factor: 7.727

7.  Leukemia-Associated Nup214 Fusion Proteins Disturb the XPO1-Mediated Nuclear-Cytoplasmic Transport Pathway and Thereby the NF-κB Signaling Pathway.

Authors:  Shoko Saito; Sadik Cigdem; Mitsuru Okuwaki; Kyosuke Nagata
Journal:  Mol Cell Biol       Date:  2016-06-15       Impact factor: 4.272

Review 8.  DEK-NUP214-Fusion Identified by RNA-Sequencing of an Acute Myeloid Leukemia with t(9;12)(q34;q15).

Authors:  Ioannis Panagopoulos; Ludmila Gorunova; Synne Torkildsen; Geir E Tjønnfjord; Francesca Micci; Sverre Heim
Journal:  Cancer Genomics Proteomics       Date:  2017 Nov-Dec       Impact factor: 4.069

Review 9.  Clinical implications of molecular markers in acute myeloid leukemia.

Authors:  Sabine Kayser; Mark J Levis
Journal:  Eur J Haematol       Date:  2018-10-23       Impact factor: 2.997

10.  The Challenge of t (6;9) and FLT3-Positive Acute Myelogenous Leukemia in a Young Adult.

Authors:  Yeohan Song; Dale Bixby; Diane Roulston; John Magenau; Sung Won Choi
Journal:  J Leuk (Los Angel)       Date:  2014
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.